Kruti Berawala examines Tata’s decision to merge Vistara into Air India, a move that seeks to blend Air India’s legacy with ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In recent years, it's often seemed like Tesla CEO Elon Musk has been too busy auditioning for the role of the next James Bond ...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update. Strengthened Cash, Strategic Refocus and Pipeline Progress De ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Constellation Energy is preparing to restart what's now called the Crane Clean Energy Center on Three Mile Island to supply ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...